Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
View Patent ↗Provided herein are methods and compositions useful in the production of recombinant AAV (rAAV) in insect cells. In some embodiments, methods and compositions include the use of modified Kozak sequences to express AAV VP1 proteins in amounts that are useful for producing infective rAAV particles.
1. A nucleic acid comprising a nucleotide sequence encoding a modified Kozak sequence and adeno-associated virus (AAV) VP1, VP2, and VP3 capsid proteins, wherein the modified Kozak sequence is selected from SEQ ID NOs: 2-11, SEQ ID NOs: 13-32, and SEQ ID NOs: 34-45.
2. The nucleic acid of claim 1 , wherein the modified Kozak sequence is SEQ ID NO: 8 or SEQ ID NO: 9.
3. The nucleic acid of claim 1 , wherein the VP1, VP2, and VP3 capsid proteins are derived from an AAV5 serotype.
4. The nucleic acid of claim 1 , further comprising a promoter sequence.
5. The nucleic acid of claim 4 , wherein the promoter sequence is a polyhedrin (polh) promoter sequence.
6. The nucleic acid of claim 1 , wherein the modified Kozak sequence contains an initiation codon for translation of the VP1 capsid protein.
7. The nucleic acid of claim 6 , wherein the initiation codon for translation of the VP1 capsid protein is AUG.
8. The nucleic acid of claim 1 , wherein the nucleic acid is packaged in a viral particle.
9. The viral particle of claim 8 , wherein the viral particle is a baculovirus particle.
10. The nucleic acid of claim 1 , wherein the modified Kozak sequence is SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32.
11. The nucleic acid of claim 1 , wherein the VP1, VP2, and VP3 capsid proteins are derived from an AAV8 serotype.
12. The nucleic acid of claim 1 , wherein the modified Kozak sequence is SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 38, or SEQ ID NO:42.
13. The nucleic acid of claim 1 , wherein the VP1, VP2, and VP3 capsid proteins are derived from an AAV9 serotype.
14. The nucleic acid of claim 1 , wherein the modified Kozak sequence comprises the sequence of SEQ ID NO: 9.
15. The nucleic acid of claim 1 , wherein the modified Kozak sequence comprises the sequence of SEQ ID NO: 42.
16. An insect cell comprising the nucleic acid of claim 1 .
17. The insect cell of claim 16 , wherein the nucleic acid is integrated into the genome of the insect cell.
18. A method of producing recombinant AAV (rAAV) in an insect cell, wherein the rAAV is derived from an AAV5 serotype, an AAV8 serotype, or an AAV9 serotype, the method comprising:
a) transfecting an insect cell with:
i) a baculovirus comprising the nucleic acid of claim 1 ;
ii) a baculovirus comprising a nucleic acid encoding an AAV Rep protein;
iii) a baculovirus comprising a nucleic acid comprising two AAV inverted terminal repeat (ITR) nucleotide sequences flanking a gene of interest operably linked to a promoter sequence;
b) culturing the insect cell under conditions suitable to produce rAAV; and
c) recovering the rAAV from the insect cell.
19. The method of claim 18 , wherein the insect cell is an Sf9 cell.
20. A method of producing recombinant AAV (rAAV) in an insect cell, wherein the rAAV is derived from an AAV5 serotype, an AAV8 serotype, or an AAV9 serotype, the method comprising:
a) transfecting an insect cell of claim 16 with a nucleic acid comprising two AAV inverted terminal repeat (ITR) nucleotide sequences flanking a gene of interest operably linked to a promoter sequence;
b) culturing the insect cell under conditions suitable to produce rAAV; and
c) recovering the rAAV from the insect cell.
21. The method of claim 20 , wherein the insect cell is an Sf9 cell.